Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19
NCT ID: NCT04493359
Last Updated: 2021-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2/PHASE3
18 participants
INTERVENTIONAL
2020-07-25
2021-09-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19
NCT04364893
The COVID-RASi Trial (COVID-19)
NCT04591210
The McGill RAAS-COVID-19 Trial
NCT04508985
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19
NCT05398731
Telmisartan in Respiratory Failure Due to COVID-19
NCT04510662
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients are going to be followed during hospital stay for evaluation of clinical endpoints. Also blood and urine samples will be acquired for evaluation of renin-angiotensin system activation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Switch therapy
Renin-angiotensin system inhibitors will be changed for other anti-hypertensive classes.
Renin-angiotensin system inhibitors
switch anti-hypertensive class
Maintenance therapy
Renin-angiotensin system inhibitors will be kept during in-hospital stay
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Renin-angiotensin system inhibitors
switch anti-hypertensive class
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed COVID-19 infection by rt-PCR, serology tests or typical clinical presentation and chest CT.
* Symptoms onset \< 96h
* Need for hospitalization
Exclusion Criteria
* Previous cerebrovascular disease
* Previous myocardial infarction
* Blood pressure \> 180 x 100 mmHg
* Need for 3 or more anti-hypertensive classes
* Use os spironolactone
* Severe pulmonary disease
* Contraindication for using other anti-hypertensive classes (calcium channel blockers, hydralazine, diuretics or nitrates)
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sao Paulo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bruno Caramelli
MD. PHD.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto do Coração - Incor HCFMUSP
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
33575220.9.0000.0068
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.